Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Yimitasvir - HEC Pharm

Drug Profile

Yimitasvir - HEC Pharm

Alternative Names: DAG 181; Yimitasvir phosphate

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HEC Pharm
  • Developer Dongguan HEC TaiGen Biopharmaceuticals; HEC Pharm
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis C

Most Recent Events

  • 26 Jun 2019 Sunshine Lake pharma plans a phase I Drug-drug Interaction study in China (PO) (ChiCTR1900021611)
  • 25 Jun 2019 Sunshine Lake Pharma completes a phase III trial in Hepatitis C (Combination therapy, Treatment-naive, Treatment-experienced) in China (PO) (NCT03487107)
  • 13 Jun 2019 Dongguan HEC TaiGen Biopharmaceuticals initiated a phase III trial in Hepatitis C (Combination therapy, treatment-naive) in China (NCT04155515)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top